AstraZeneca PLC Director/PDMR Shareholding (5368T)
March 25 2021 - 10:00AM
UK Regulatory
TIDMAZN
RNS Number : 5368T
AstraZeneca PLC
25 March 2021
25 March 2021 15:00 GMT
Transactions by Persons Discharging Managerial
Responsibilities
AstraZeneca PLC (the Company) announced that, on 23 and 24 March
2021, awards of the Company's ordinary shares of $0.25 each
(Ordinary Shares) vested to certain Persons Discharging Managerial
Responsibilities of the Company (PDMRs) under the AstraZeneca
Deferred Bonus Plan (AZDBP) and AstraZeneca Performance Share Plans
(AZPSP).
The AZDBP award was granted on 23 March 2018, following the
deferral of a portion of each PDMR's annual bonus paid in respect
of 2017 performance into Ordinary Shares, and vested on completion
of the three-year holding period.
The AZPSP award was granted on 24 March 2016 and was subject to
a three-year performance period. On the third anniversary of grant
the award was placed in a two-year holding period. The award vested
at the end of that holding period. Application of the performance
measures specified at the time of grant resulted in 79% of the
AZPSP award vesting and the remaining unvested part lapsing.
Following the reinvestment of dividends accrued during the
performance and holding periods of the AZPSP award and during the
deferral period of the AZDBP award, and the withholding of shares
to satisfy certain tax obligations arising on vesting, the PDMRs'
beneficial interests in Ordinary Shares changed as detailed in the
table below:
PDMR Ordinary Shares Ordinary Shares
acquired under the acquired under the
AZDBP AZPSP
Pascal Soriot 13,241 110,966
-------------------- --------------------
Marc Dunoyer 4,214 27,355
-------------------- --------------------
For tax purposes, the fair market value of an Ordinary Share at
vest of the AZDBP award was 7344 pence, being the closing price on
the last trading day preceding the vesting. The fair market value
of an Ordinary Share at vest of the AZPSP award was 7215 pence,
being the closing price on the last trading day preceding the
vesting.
Further details are set out in the attached notifications, made
in accordance with the requirements of the EU and UK Market Abuse
Regulations.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Pascal Soriot
-------------------------- ---------------------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Chief Executive Officer
-------------------------- ---------------------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------- ---------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name AstraZeneca PLC
-------------------------- ---------------------------------------------
b) LEI PY6ZZQWO2IZFZC3IOL08
-------------------------- ---------------------------------------------
4i Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------------
a) Description of the Ordinary Shares of US$0.25 each in
financial instrument, AstraZeneca PLC
type of instrument
Identification code GB0009895292
-------------------------- ---------------------------------------------
b) Nature of the transaction Acquisition of ordinary shares pursuant
to a vesting under the AstraZeneca
Deferred Bonus Plan, for nil consideration.
-------------------------- ---------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
0 13,241
----------
-------------------------- ---------------------------------------------
d) Aggregated information Not applicable - single transaction
- Aggregated volume
- Price
-------------------------- ---------------------------------------------
e) Date of the transaction 23 March 2021
-------------------------- ---------------------------------------------
f) Place of the transaction Outside a trading venue
-------------------------- ---------------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Marc Dunoyer
-------------------------- ---------------------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Chief Financial Officer
-------------------------- ---------------------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------- ---------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name AstraZeneca PLC
-------------------------- ---------------------------------------------
b) LEI PY6ZZQWO2IZFZC3IOL08
-------------------------- ---------------------------------------------
4i Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------------
a) Description of the Ordinary Shares of US$0.25 each in
financial instrument, AstraZeneca PLC
type of instrument
Identification code GB0009895292
-------------------------- ---------------------------------------------
b) Nature of the transaction Acquisition of ordinary shares pursuant
to a vesting under the AstraZeneca
Deferred Bonus Plan, for nil consideration.
-------------------------- ---------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
0 4,214
----------
-------------------------- ---------------------------------------------
d) Aggregated information Not applicable - single transaction
- Aggregated volume
- Price
-------------------------- ---------------------------------------------
e) Date of the transaction 23 March 2021
-------------------------- ---------------------------------------------
f) Place of the transaction Outside a trading venue
-------------------------- ---------------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Pascal Soriot
-------------------------- ------------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------
a) Position/status Chief Executive Officer
-------------------------- ------------------------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------- ------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------
a) Name AstraZeneca PLC
-------------------------- ------------------------------------------------
b) LEI PY6ZZQWO2IZFZC3IOL08
-------------------------- ------------------------------------------------
4i Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------------
a) Description of the Ordinary Shares of US$0.25 each in
financial instrument, AstraZeneca PLC
type of instrument
Identification code GB0009895292
-------------------------- ------------------------------------------------
b) Nature of the transaction Acquisition of ordinary shares pursuant
to a vesting under the AstraZeneca
Performance Share Plan, for nil consideration.
-------------------------- ------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
0 110,966
----------
-------------------------- ------------------------------------------------
d) Aggregated information Not applicable - single transaction
- Aggregated volume
- Price
-------------------------- ------------------------------------------------
e) Date of the transaction 24 March 2021
-------------------------- ------------------------------------------------
f) Place of the transaction Outside a trading venue
-------------------------- ------------------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Marc Dunoyer
-------------------------- ------------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------
a) Position/status Chief Financial Officer
-------------------------- ------------------------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------- ------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------
a) Name AstraZeneca PLC
-------------------------- ------------------------------------------------
b) LEI PY6ZZQWO2IZFZC3IOL08
-------------------------- ------------------------------------------------
4i Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------------
a) Description of the Ordinary Shares of US$0.25 each in
financial instrument, AstraZeneca PLC
type of instrument
Identification code GB0009895292
-------------------------- ------------------------------------------------
b) Nature of the transaction Acquisition of ordinary shares pursuant
to a vesting under the AstraZeneca
Performance Share Plan, for nil consideration.
-------------------------- ------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
0 27,355
----------
-------------------------- ------------------------------------------------
d) Aggregated information Not applicable - single transaction
- Aggregated volume
- Price
-------------------------- ------------------------------------------------
e) Date of the transaction 24 March 2021
-------------------------- ------------------------------------------------
f) Place of the transaction Outside a trading venue
-------------------------- ------------------------------------------------
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three therapy areas -
Oncology, Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. Please visit astrazeneca.com and
follow the Company on Twitter @ AstraZeneca .
Contacts
For details on how to contact the Investor Relations Team,
please click here . For Media contacts, click here .
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHUVASRANUOUAR
(END) Dow Jones Newswires
March 25, 2021 11:00 ET (15:00 GMT)
Astrazeneca (LSE:0A4J)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astrazeneca (LSE:0A4J)
Historical Stock Chart
From Apr 2023 to Apr 2024
